Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications
Sebastian E Sattui1, Angelo L Gaffo2
1Tinsley Harrison Internal Medicine Residency Program, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Insights
Gout management is improving with new therapies targeting hyperuricemia. Emerging drugs show promise for better control of high uric acid levels and reducing gout complications.
Area of Science:
- Rheumatology
- Pharmacology
Background:
- Gout, the most common inflammatory arthritis, is frequently poorly managed.
- Hyperuricemia is linked to cardiometabolic issues and poor patient outcomes like disability.
Purpose of the Study:
- To review current gout therapeutic strategies and their limitations.
- To discuss emerging agents for chronic hyperuricemia management in gout.
Main Methods:
- Review of current literature on gout management.
- Analysis of drugs in development (Phases I and II).
Main Results:
- Limited therapeutic options for hyperuricemia have existed for decades.
- New uricosurics (e.g., lesinurad, arhalofenate) are developed based on renal urate transporter knowledge.
Conclusions:
- Emerging agents, including purine nucleoside phosphorylase inhibitors and dual-action drugs, offer hope.
- New developments may lead to more adequate hyperuricemia management in gout patients.
Abstract:
Despite being the most common type of inflammatory arthritis, gout is often poorly managed. Except for febuxostat and pegloticase, research in new therapeutic agents for the management of hyperuricemia in gout remained insufficient for several decades. With emerging evidence of possible roles of hyperuricemia in cardiometabolic comorbidities, as well as more convincing evidence regarding poor outcomes (e.g. disability, recurrent hospital admissions) in patients with uncontrolled gout, several agents are current under development. Increasing knowledge regarding renal urate transporters has resulted in the development of new generation uricosurics such as lesinurad and arhalofenate. This review aims at discussing current therapeutic strategies for gout, as well as their limitations and the possible role of emerging agents in the chronic management of hyperuricemia in gout. Drugs in phases I and II of development will be discussed, along with new agents and therapeutic classes, such as purine nucleoside phosphorylase inhibitors and dual-action drugs. These new developments are encouraging, and will hopefully contribute to a more adequate management of hyperuricemia in gout.
Related Concept Videos
Urinary Tract Calculi III: Medical Management
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Pharmaceutical Poisoning: Treatment Strategies
Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations
Peripheral Artery Disease III: Interprofessional Care
![Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F61682.jpg&w=3840&q=50)

